The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
The concept of immune surveillance against tumors: The first theories
Open accessAbstract
// Domenico Ribatti 1,2 1 Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy 2 National Cancer Institute “Giovanni Paolo II”, Bari, Italy Correspondence to: Domenico Ribatti, email: // Keywords : Antigen; immune surveillance; history of medicine; T cell; tumor Received : July 18, 2016 Accepted : October 10, 2016 Published : October 18, 2016 Abstract The immune system plays a major role in the surveillance against tumors. To avoid attack from the immune system, tumor cells develop different strategies to escape immune surveillance. Evidence of immune surveillance comes from both animal models and clinical observations. Mice with a wide variety of immunodeficiencies have a high rate of tumor incidence and are more susceptible to transplanted or chemical carcinogen-induced tumors. Immunosuppressed patients have a high incidence of tumors. However, many patients develop cancer even in the presence of an apparently normal immune system. This indicates that tumor cells are able to escape immune surveillance. The aim of this review article is to summarize the literature concerning the development of the theory of immune surveillance against tumors; to discuss the evidence for and against this theory, and to discuss the concept of immunoediting. Finally, the current approaches in anti-tumor immunotherapy will be analyzed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5022.779 · Cited by 810
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin.
Ej, F. (1953) · PubMed · Cited by 690
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614
Merkel cell carcinoma and HIV infection
Engels, E. A., Frisch, M., Goedert, J. J., Biggar, R. J., & Miller, R. W. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07668-7 · Cited by 550
Decreased tumor surveillance in perforin-deficient mice.
van den Broek, M. E., Kägi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W. K., Melief, C. J., Zinkernagel, R. M., & Hengartner, H. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1781 · Cited by 512
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 438
Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line
Gross, L. (1943) · Cancer Research · Cited by 360
Lymphocytic infiltration and survival in rectal cancer.
Jass, J. R. (1986) · Journal of Clinical Pathology · doi:10.1136/jcp.39.6.585 · Cited by 356
Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice
Stutman, O. (1974) · Science · doi:10.1126/science.183.4124.534 · Cited by 356
From mice to humans: developments in cancer immunoediting
Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80004 · Cited by 337
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
Philips, G. K., & Atkins, M. (2015) · International Immunology · doi:10.1093/intimm/dxu095 · Cited by 335
Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381804 · Cited by 308
Immunodepression and Malignancy
(1976) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60179-7 · Cited by 308
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Cancer in the Transplant Recipient
Chapman, J. R., Webster, A. C., & Wong, G. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015677 · Cited by 275
Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells
Street, S. E. A., Hayakawa, Y., Zhan, Y., Lew, A. M., MacGregor, D., Jamieson, A. M., Diefenbach, A., Yagita, H., Godfrey, D. I., & Smyth, M. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031981 · Cited by 264
Does the Immune System Naturally Protect Against Cancer?
Corthay, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00197 · Cited by 261
Rilke, F., Colnaghi, M. I., Cascinelli, N., Andreola, S., Baldini, M. T., Bufalino, R., Porta, G. D., Ménard, S., Pierotti, M. A., & Testori, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490109 · Cited by 259
Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation
Stewart, T., Tsai, S.-C., Grayson, H., Henderson, R., & Opelz, G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91618-0 · Cited by 235
Mesri, E. A., Cesarman, E., Arvanitakis, L., Rafii, S., Moore, M. A. S., Posnett, D. N., Knowles, D., & Asch, A. S. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.5.2385 · Cited by 233
Tumors of the Immunocompromised Patient
Penn, I. (1988) · Annual Review of Medicine · doi:10.1146/annurev.me.39.020188.000431 · Cited by 229
Dhodapkar, M. V., Krasovsky, J., Osman, K., & Geller, M. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031030 · Cited by 217
Palma, L., Di Lorenzo, N., & Guidetti, B. (1978) · Journal of Neurosurgery · doi:10.3171/jns.1978.49.6.0854 · Cited by 206
A proportion of patients with lymphoma may harbor mutations of the perforin gene
Clementi, R. (2005) · Blood · doi:10.1182/blood-2004-04-1477 · Cited by 188
The DNA Damage Response Arouses the Immune System
Gasser, S., & Raulet, D. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4603 · Cited by 178
Pawelec, G., Derhovanessian, E., & Larbi, A. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.06.012 · Cited by 173
Potential role of immunosenescence in cancer development
Fulop, T., Kotb, R., Fortin, C. F., Pawelec, G., de Angelis, F., & Larbi, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05370.x · Cited by 159
Chlamydia trachomatis infection: implications for HPV status and cervical cancer
Silva, J., Cerqueira, F., & Medeiros, R. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-3122-3 · Cited by 152
Lipponen, P., Eskelinen, M. J., Jauhiainen, K., Harju, E., & Terho, R. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90579-5 · Cited by 139
He, Y., Zhang, G., Wang, X., Zhang, H., Yuan, Y., Li, D., & Feng, Z. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4919 · Cited by 126
Cancer and viral infections in immunocompromised individuals
Schulz, T. F. (2009) · International Journal of Cancer · doi:10.1002/ijc.24741 · Cited by 123
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer.
Jett, J. R., Maksymiuk, A. W., Su, J. Q., Mailliard, J. A., Krook, J. E., Tschetter, L. K., Kardinal, C. G., Twito, D. I., Levitt, R., & Gerstner, J. B. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2321 · Cited by 118
Spontaneous and induced tumor incidence in germfree "nude" mice.
Outzen, H. C., Custer, R. P., Eaton, G. J., & Prehn, R. T. (1975) · PubMed · Cited by 90
Tumour Targeting with Systemically Administered Bacteria
Morrissey, D., O’Sullivan, G. C., & Tangney, M. (2010) · Current Gene Therapy · doi:10.2174/156652310790945575 · Cited by 90
Epstein–Barr Virus, the Immune System, and Associated Diseases
Chen, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00005 · Cited by 83
Wiesenfeld, M., O'Connell, M. J., Wieand, H. S., Gonchoroff, N. J., Donohue, J. H., Fitzgibbons, R. J., Krook, J. E., Mailliard, J. A., Gerstner, J. B., & Pazdur, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2324 · Cited by 64
Prognostic significance of histologic host response in cancer of the large bowel
Nacopoulou, L., Azaris, P., Papacharalampous, N. X., & Davaris, P. (1981) · Cancer · Cited by 61
Cancer treatment: The killer within
Ledford, H. K. (2014) · Nature · doi:10.1038/508024a · Cited by 51
Prostatic carcinoma.Some morphological features affecting prognosis
Epstein, N. A., & Fatti, L. (1976) · Cancer · Cited by 46
Perforin-mediated suppression of B-cell lymphoma
Bolitho, P., Street, S. E. A., Westwood, J. A., Edelmann, W., MacGregor, D. P., Waring, P., Murray, W. K., Godfrey, D. I., Trapani, J. A., Johnstone, R. W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809008106 · Cited by 45
Helicobacter pylori and gastric cancer
McFarlane, G. A., & Munro, A. (1997) · British journal of surgery · doi:10.1046/j.1365-2168.1997.02874.x · Cited by 42
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
Gulley, J. L., Mulders, P., Albers, P., Banchereau, J., Bolla, M., Pantel, K., & Powles, T. B. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1107698 · Cited by 40
Histologic correlates of virulence in ovarian adenocarcinoma
Deligdisch, L., Jacobs, A. J., & Cohen, C. J. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90178-8 · Cited by 31
Immune Response to Premalignancy: Insights from Patients with Monoclonal Gammopathy
Dhodapkar, M. V. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1358.004 · Cited by 11
Cited by
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J., & Lim, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 751
Immunogenic cell death in cancer therapy: Present and emerging inducers
Zhou, J., Wang, G., Chen, Y., Wang, H., Hua, Y., & Cai, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14356 · Cited by 719
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C.-M., Italiano, A., & Sautès-Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 657
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Liu, J., Peng, Y., & Wei, W. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.07.001 · Cited by 372
Oncolytic virus immunotherapy: future prospects for oncology
Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0458-z · Cited by 313
Metadata
- Authors
- Ribatti, D.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-10-18
- Volume
- 8
- Issue
- 4
- Pages
- 7175-7180
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2534058713
- Cited by
- 332
- References
- 59
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.